Epimacular brachytherapy for wet AMD: current perspectives

Ricardo P Casaroli-Marano,1,2 Socorro Alforja,1 Joan Giralt,1 Michel E Farah2 1Instituto Clínic de Oftalmología (Hospital Clínic de Barcelona), University of Barcelona, Barcelona, Spain; 2Department of Ophthalmology and Visual Sciences, Universidade Federal de Sao...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Casaroli-Marano RP, Alforja S, Giralt J, Farah ME
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/b5203c35538445f3b3e7f156c7aeb450
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b5203c35538445f3b3e7f156c7aeb450
record_format	dspace
spelling	oai:doaj.org-article:b5203c35538445f3b3e7f156c7aeb4502021-12-02T00:13:26ZEpimacular brachytherapy for wet AMD: current perspectives1177-5483https://doaj.org/article/b5203c35538445f3b3e7f156c7aeb4502014-08-01T00:00:00Zhttp://www.dovepress.com/epimacular-brachytherapy-for-wet-amd-current-perspectives-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483 Ricardo P Casaroli-Marano,1,2 Socorro Alforja,1 Joan Giralt,1 Michel E Farah2 1Instituto Clínic de Oftalmología (Hospital Clínic de Barcelona), University of Barcelona, Barcelona, Spain; 2Department of Ophthalmology and Visual Sciences, Universidade Federal de Sao Paulo, Escola Paulista de Medicina, Sao Paulo, Brazil Abstract: Age-related macular degeneration (AMD) is considered the most common cause of blindness in the over-60 age group in developed countries. There are basically two forms of presentation: geographic (dry or atrophic) and wet (neovascular or exudative). Geographic atrophy accounts for approximately 85%–90% of ophthalmic frames and leads to a progressive degeneration of the retinal pigment epithelium and the photoreceptors. Wet AMD causes the highest percentage of central vision loss secondary to disease. This neovascular form involves an angiogenic process in which newly formed choroidal vessels invade the macular area. Today, intravitreal anti-angiogenic drugs attempt to block the angiogenic events and represent a major advance in the treatment of wet AMD. Currently, combination therapy for wet AMD includes different forms of radiation delivery. Epimacular brachytherapy (EMBT) seems to be a useful approach to be associated with current anti-vascular endothelial growth factor agents, presenting an acceptable efficacy and safety profile. However, at the present stage of research, the results of the clinical trials carried out to date are insufficient to justify extending routine use of EMBT for the treatment of wet AMD. Keywords: macular degeneration, radiation, vascular endothelial growth factor, combined therapy, intravitreal therapy, vitrectomyCasaroli-Marano RPAlforja SGiralt JFarah MEDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2014, Iss default, Pp 1661-1670 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Casaroli-Marano RP Alforja S Giralt J Farah ME Epimacular brachytherapy for wet AMD: current perspectives
description	Ricardo P Casaroli-Marano,1,2 Socorro Alforja,1 Joan Giralt,1 Michel E Farah2 1Instituto Clínic de Oftalmología (Hospital Clínic de Barcelona), University of Barcelona, Barcelona, Spain; 2Department of Ophthalmology and Visual Sciences, Universidade Federal de Sao Paulo, Escola Paulista de Medicina, Sao Paulo, Brazil Abstract: Age-related macular degeneration (AMD) is considered the most common cause of blindness in the over-60 age group in developed countries. There are basically two forms of presentation: geographic (dry or atrophic) and wet (neovascular or exudative). Geographic atrophy accounts for approximately 85%–90% of ophthalmic frames and leads to a progressive degeneration of the retinal pigment epithelium and the photoreceptors. Wet AMD causes the highest percentage of central vision loss secondary to disease. This neovascular form involves an angiogenic process in which newly formed choroidal vessels invade the macular area. Today, intravitreal anti-angiogenic drugs attempt to block the angiogenic events and represent a major advance in the treatment of wet AMD. Currently, combination therapy for wet AMD includes different forms of radiation delivery. Epimacular brachytherapy (EMBT) seems to be a useful approach to be associated with current anti-vascular endothelial growth factor agents, presenting an acceptable efficacy and safety profile. However, at the present stage of research, the results of the clinical trials carried out to date are insufficient to justify extending routine use of EMBT for the treatment of wet AMD. Keywords: macular degeneration, radiation, vascular endothelial growth factor, combined therapy, intravitreal therapy, vitrectomy
format	article
author	Casaroli-Marano RP Alforja S Giralt J Farah ME
author_facet	Casaroli-Marano RP Alforja S Giralt J Farah ME
author_sort	Casaroli-Marano RP
title	Epimacular brachytherapy for wet AMD: current perspectives
title_short	Epimacular brachytherapy for wet AMD: current perspectives
title_full	Epimacular brachytherapy for wet AMD: current perspectives
title_fullStr	Epimacular brachytherapy for wet AMD: current perspectives
title_full_unstemmed	Epimacular brachytherapy for wet AMD: current perspectives
title_sort	epimacular brachytherapy for wet amd: current perspectives
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/b5203c35538445f3b3e7f156c7aeb450
work_keys_str_mv	AT casarolimaranorp epimacularbrachytherapyforwetamdcurrentperspectives AT alforjas epimacularbrachytherapyforwetamdcurrentperspectives AT giraltj epimacularbrachytherapyforwetamdcurrentperspectives AT farahme epimacularbrachytherapyforwetamdcurrentperspectives
_version_	1718403885098336256

Epimacular brachytherapy for wet AMD: current perspectives

Ejemplares similares